FIG 2.

Time-to-event analyses for (A) duration of response; (B) progression-free survival; (C) time to CNS progression (deaths censored) in all patients (blue) and in patients with (gray) or without (red) baseline CNS metastases by investigator assessment; and (D) overall survival, in patients with ROS1 fusion–positive non–small-cell lung cancer (N = 161). For patients without CNS metastases at baseline, CNS progressive disease was detected either through scans triggered by symptoms suggestive of CNS disease or scans performed routinely at the investigator's discretion, since brain scans were not mandated by the protocol.